Fractional radiofrequency microneedling device clears predicate pathway; adds competition to InMode and Cutera.
VIOL Medical secured FDA 510(k) clearance for Scarlet Pro, a fractional radiofrequency microneedling system. The clearance is based on substantial equivalence to existing RF microneedling predicates, meaning VIOL can now market and sell in the U.S.
Scarlet Pro enters a crowded RF microneedling space dominated by InMode's Morpheus8 and Cutera's Secret RF. The 510(k) pathway—faster and cheaper than PMA—is standard for RF microneedling devices. What matters is clinical differentiation: depth of penetration, energy delivery, handpiece ergonomics, and treatment time. VIOL will need to compete on price, training support, and outcomes data.
VIOL Scarlet Pro clears FDA 510(k) for RF microneedling
For practices already invested in Morpheus8 or Secret RF, Scarlet Pro is a third option to evaluate. Expect VIOL to offer aggressive lease terms and per-treatment rebates to gain market share. If you're considering RF microneedling, request clinical data and compare cost per treatment across platforms.
Source: original report ↗
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/mo
Join the owners who run ahead of the industry. Cancel anytime, one click.
